Evolution of tick vaccinology by José de la Fuente, Srikant Ghosh, Ala Tabor

“…Future directions will advance in these areas together with other novel technologies such as multiomics, AI and Big Data, mRNA vaccines, microbiota-driven probiotics and vaccines, and combination of vaccines with other interventions in collaboration with regions with high incidence of tick infestations and tick-borne diseases for a personalized medicine approach.…”
Get full text

A review of COVID-19 vaccination and the reported cardiac manifestations by Jamie Sin Ying Ho, Ching-Hui Sia, Jinghao Nicholas Ngiam, Poay Huan Loh, Nicholas Wen Sheng Chew, William Kok-Fai Kong, Kian-Keong Poh

“…Reported COVID-19 vaccine-associated cardiac adverse events were mainly myocarditis and pericarditis, most commonly seen in adolescent and young adult male individuals after mRNA vaccination. Reports of other events such as acute myocardial infarction, arrhythmia and stress cardiomyopathy were rare. …”
Get full text

Entangled evidence: epistemic injustice, and systemic neglect in the assessment of menstrual disorders following COVID-19 vaccines by Maurizia Mezza

“…While some presumed side effects were swiftly assessed, others, such as menstrual disorders following mRNA vaccination, were subjected to prolonged debates. …”
Get full text

COVID-19 Booster Vaccines Administration in Different Countries by Angel Yun-Kuan Thye, Loh Teng-Hern Tan, Jodi Woan Fei Law, Vengadesh Letchumanan

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that resulted in the COVID-19 global pandemic had consequently led to the development of different types of COVID-19 vaccines, including the messenger RNA (mRNA) vaccines, inactivated virus vaccines, a protein subunit vaccine, and viral vector recombinant vaccines. …”
Get full text

The effect of COVID-19 and COVID-19 vaccines on chronic spontaneous urticaria: single center experience by Öner Özdemir, Ümmügülsüm Dikici

“…As a result, omalizumab had to be started in 3/8 patients after mRNA vaccination due to CSU exacerbation or treatment failure. …”
Get full text

A Case of TAFRO Syndrome Developed after COVID-19 Vaccination by Hitomi Hirose, Hitoshi Suzuki, Yukako Umezawa, Masako Iwasaki, Hiromitsu Fukuda, Hisatsugu Takahara, Shigeki Tomita, Yusuke Suzuki

“…TAFRO syndrome that progresses after the COVID-19 mRNA vaccination has not yet been reported. A 45-year-old man developed fever, gross hematuria, renal dysfunction, pleural effusions, and ascites immediately after vaccination. …”
Get full text

Modern vaccines and coronavirus infections by Yu. A. Belikova, Yu. V. Samsonov, E. V. Abakushina

“…This review is on recent advances in the development of new generation vaccines, as well as those developed using earlier time-tested technologies: live attenuated vaccines, inactivated vaccines, recombinant vaccines, subunit vaccines, virus-like particle-based vaccines, synthetic peptide vaccines, DNA vaccines and mRNA vaccines. However, many infections are still not preventable with the currently available vaccines and they represent a major cause of mortality worldwide — for example, severe acute respiratory syndrome coronavirus, middle east respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 — COVID-19. …”
Get full text

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants by Tanmay Ghildiyal, Nishant Rai, Janhvi Mishra Rawat, Maargavi Singh, Jigisha Anand, Gaurav Pant, Gaurav Kumar, Amrullah Shidiki

“…The review provides an integrative discussion on the current state of knowledge on the type of vaccines developed against SARS-CoV-2, the safety and efficacy of COVID-19 vaccines concerning the VOCs, and prospects of novel universal, chimeric, and bivalent mRNA vaccines efficacy to fend off existing variants and other emerging coronaviruses. …”
Get full text

COVID-19: Understanding the New Variants of Concern by Ke-Yan Loo, Vengadesh Letchumanan

“…Fortunately, early evidence shows that the mRNA vaccines are still effective against the current circulating Omicron sublineages of the coronavirus. …”
Get full text

Optimization of Conditions for Production of Soluble <i>E. coli</i> Poly(A)-Polymerase for Biotechnological Applications by Igor P. Oscorbin, Maria S. Kunova, Maxim L. Filipenko

“…In vitro, PAP 1 is used to prepare libraries for RNAseq and to produce mRNA vaccines. However, <i>E. coli</i> PAP 1’s toxicity and instability in low-salt buffers complicate its expression and purification. …”
Get full text

Disparities in response to mRNA SARS-CoV-2 vaccines according to sex and age: A systematic review by Michelle Bachmann, Nejla Gültekin, Zeno Stanga, Jan S. Fehr, Ismail I. Ülgür, Patricia Schlagenhauf

“…The results showed that the COVID-19 mRNA vaccines typically elicit robust immune responses, and that younger people have higher antibody levels. …”
Get full text

Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms by Nadezhda Wall, Rachel Lamerton, Fiona Ashford, Marisol Perez-Toledo, Aleksandra Jasiulewicz, Gemma D. Banham, Maddy L. Newby, Sian E. Faustini, Alex G. Richter, Haresh Selvaskandan, Roseanne E. Billany, Sherna F. Adenwalla, Ian R. Henderson, Max Crispin, Matthew Graham-Brown, Lorraine Harper, Adam F. Cunningham

“…Encouragingly, exploiting immunological memory by using mRNA vaccines and boosting may improve the success of vaccination strategies in this vulnerable patient population.…”
Get full text

TCR transgenic clone selection guided by immune receptor analysis and single-cell RNA expression of polyclonal responders by Nincy Debeuf, Sahine Lameire, Manon Vanheerswynghels, Julie Deckers, Caroline De Wolf, Wendy Toussaint, Rein Verbeke, Kevin Verstaen, Hamida Hammad, Stijn Vanhee, Bart N Lambrecht

“…After immunization with Spike/CpG-motifs, mRNA vaccination or SARS-CoV-2 infection, CORSET8 T cells strongly proliferated and showed signs of T cell activation. …”
Get full text

Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms by Mie Suzuki Okutani, Shinya Okamura, Tang Gis, Hitomi Sasaki, Suni Lee, Akiho Kashiwabara, Simon Goto, Mai Matsumoto, Mayuko Yamawaki, Toshiaki Miyazaki, Tatsuya Nakagawa, Masahito Ikawa, Wataru Kamitani, Shiro Takekawa, Koichi Yamanishi, Hirotaka Ebina

“…mRNA vaccines against SARS-CoV-2 were rapidly developed and were effective during the pandemic. …”
Get full text

Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing by Chin Shern Lau, Helen M. L. Oh, Tar Choon Aw

“…Spike antibodies tracked the rise in antibodies after vaccination with mRNA vaccines and became invaluable in the assessment of vaccine response. …”
Get full text

Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review by Nidhi Garg, Ananya Sree Kunamneni, Pankaj Garg, Sandeep Sharma, Divakar Sharma, Adinarayana Kunamneni

“…Regarding vaccine efficacy (VE), the 3-dose VE with mRNA vaccines at 14–60 days was found to be 71.6%, and after 60 days, it is 47.4%. …”
Get full text

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera by Thomas E. Hickey, Uma Mudunuri, Heidi A. Hempel, Troy J. Kemp, Nancy V. Roche, Keyur Talsania, Brian A. Sellers, James M. Cherry, Ligia A. Pinto

“…However, little is known about the proteomic markers and pathways associated with host immune responses to mRNA vaccination. In this proof-of-concept study, sera from male and female vaccine recipients were evaluated for proteomic and immunologic responses 1-month and 6-months following homologous third vaccination.MethodsAn aptamer-based (7,289 marker) proteomic assay coupled with traditional serology was leveraged to generate a comprehensive evaluation of systemic responsiveness in 64 and 68 healthy recipients of mRNA-1273 and BNT162b2 vaccines, respectively.ResultsSera from female recipients of mRNA-1273 showed upregulated indicators of inflammatory and immunological responses at 1-month post-third vaccination, and sera from female recipients of BNT162b2 demonstrated upregulated negative regulators of RNA sensors at 1-month. …”
Get full text

Exploring Future Pandemic Preparedness Through the Development of Preventive Vaccine Platforms and the Key Roles of International Organizations in a Global Health Crisis by Jihee Jeon, Eunyoung Kim

“…Despite initial concerns, the swift integration of cutting-edge development technologies, mass production capabilities, and global collaboration have made messenger RNA (mRNA) vaccines a game-changing technology. As a result of the successful application of novel vaccine platforms, it is important to address the remaining challenges, including technical limits, safety concerns, and equitable global distribution. …”
Get full text